Technical Analysis for RANI - Rani Therapeutics Holdings, Inc.

Grade Last Price % Change Price Change
D 18.08 0.11% 0.02
RANI closed up 0.11 percent on Friday, September 24, 2021, on 5 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong N/A N/A Down
Historical RANI trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
Stochastic Reached Oversold Weakness 0.11%
Lower Bollinger Band Touch Weakness 0.11%
Oversold Stochastic Weakness 0.11%
Fell Below 20 DMA Bearish 2.38%
Crossed Above 20 DMA Bullish -6.32%
Narrow Range Bar Range Contraction -6.32%
20 DMA Resistance Bearish -3.93%
Older End-of-Day Signals for RANI ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible NR7 about 16 hours ago
Up 5% about 16 hours ago
Up 3% about 17 hours ago
Up 2% about 17 hours ago
60 Minute Opening Range Breakout about 18 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Rani Therapeutics Holdings, Inc. Description

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-103, a glucagon-like peptide-1 mimetic to treat type 2 diabetes; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was founded in 2012 and is headquartered in San Jose, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Diabetes Anatomy Endocrine System Osteoporosis Peptide Hormones Growth Hormone Acromegaly Glands Growth Hormone Deficiency Neuroendocrine Tumors Parathyroid Hormone Glucagon Neuroendocrinology Growth Hormones Hypoparathyroidism Octreotide Psoriatic Arthritis Treatment Of Osteoporosis

Is RANI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 29.4
52 Week Low 9.24
Average Volume 401,720
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 19.12
10-Day Moving Average 19.02
Average True Range 2.02
ADX 43.45
+DI 24.95
-DI 15.13
Chandelier Exit (Long, 3 ATRs) 18.46
Chandelier Exit (Short, 3 ATRs) 23.16
Upper Bollinger Bands 20.95
Lower Bollinger Band 17.29
Percent B (%b) 0.22
BandWidth 19.15
MACD Line 0.61
MACD Signal Line 1.06
MACD Histogram -0.4495
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.42
Resistance 3 (R3) 19.54 19.22 19.20
Resistance 2 (R2) 19.22 18.88 19.16 19.12
Resistance 1 (R1) 18.65 18.67 18.49 18.53 19.05
Pivot Point 18.32 18.32 18.24 18.26 18.32
Support 1 (S1) 17.76 17.98 17.59 17.63 17.11
Support 2 (S2) 17.43 17.77 17.37 17.04
Support 3 (S3) 16.86 17.43 16.96
Support 4 (S4) 16.74